Related Experiment Video

Updated: Jul 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate

O Kosmider1, N Denis, P Dubreuil

  • 1Inserm U528, Institut Curie, Paris cedex 05, France.

Oncogene
|December 19, 2006
PubMed

Insights

The tyrosine kinase inhibitor SU5416 effectively halts cancer cell growth and triggers apoptosis in Kit-mutated cells resistant to imatinib mesylate (Gleevec). This drug shows promise for treating cancers with oncogenic Kit mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Activating mutations in the Kit receptor tyrosine kinase are common in various cancers.
  • Specific Kit mutations, like Asp 816, confer resistance to imatinib mesylate (Gleevec).
  • Erythroleukemic cells with Kit mutations (D814Y, D814V, D818Y) were utilized.

Purpose of the Study:

  • To evaluate the efficacy of the tyrosine kinase inhibitor SU5416 (Semaxinib) against Kit-driven cancers.
  • To investigate SU5416's mechanism of action in Kit-mutated cells resistant to imatinib.

Main Methods:

  • In vitro studies using erythroleukemic cells from Spi-1/PU.1 transgenic mice.
  • Assessment of SU5416's effect on cell growth, apoptosis, and downstream signaling pathways.
  • Analysis of Kit autophosphorylation and activation of Akt, Erk1/Erk2, and Stat3.

Main Results:

  • SU5416 induced significant growth arrest and apoptosis in erythroleukemic cells.
  • The observed effects were independent of the specific Kit mutation type.
  • SU5416 effectively inhibited Kit autophosphorylation and downstream signaling (Akt, Erk1/Erk2, Stat3).

Conclusions:

  • SU5416 demonstrates potent anti-cancer activity against Kit mutations resistant to imatinib.
  • SU5416 represents a potential therapeutic strategy for malignancies driven by imatinib-resistant Kit oncogenic mutations.

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...